Press Release: AMCP Praises the House E&C Subcommittee on Health for Advancing H.R. 2026 ‘Pharmaceutical Information Exchange (PIE) Act of 2017’
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, comments on today's unanimous vote by the House Energy & Commerce (E&C) Committee to approve legislation reauthorizing the FDA’s user fee programs.
